| Human immunodeficiency virus I infection
Edurant vs Triumeq
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Edurant vs Triumeq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTriumeq has a higher rate of injection site reactions vs Edurant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Triumeq but not Edurant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edurant
Triumeq
At A Glance
Oral
Once daily
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Oral
Once daily
INSTI + dual NRTI antiretroviral combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 25 mg oral tablet once daily with a meal for patients weighing at least 25 kg. Pediatric patients 2 years and older weighing 14-20 kg receive 12.5 mg (5 x 2.5 mg dispersed tablets); 20-25 kg receive 15 mg (6 x 2.5 mg dispersed tablets). During pregnancy with virologic suppression, 25 mg once daily with a meal. When coadministered with rifabutin, increase to 50 mg (two 25 mg tablets) once daily with a meal.
Human immunodeficiency virus I infection Adults: One tablet of TRIUMEQ (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once daily orally with or without food. Pediatric patients >=25 kg: One tablet TRIUMEQ once daily. Pediatric patients 6 to <10 kg: 3 tablets TRIUMEQ PD (180 mg abacavir, 15 mg dolutegravir, 90 mg lamivudine) once daily dispersed in water. Pediatric patients 10 to <14 kg: 4 tablets TRIUMEQ PD (240 mg abacavir, 20 mg dolutegravir, 120 mg lamivudine) once daily dispersed in water. Pediatric patients 14 to <20 kg: 5 tablets TRIUMEQ PD (300 mg abacavir, 25 mg dolutegravir, 150 mg lamivudine) once daily dispersed in water. Pediatric patients 20 to <25 kg: 6 tablets TRIUMEQ PD (360 mg abacavir, 30 mg dolutegravir, 180 mg lamivudine) once daily dispersed in water. Screen for HLA-B*5701 allele and test for HBV infection before initiating. Adjust dolutegravir to 50 mg twice daily when coadministered with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (more than single-dose treatment)
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Presence of HLA-B*5701 allele
- Prior hypersensitivity reaction to abacavir, dolutegravir, or lamivudine
- Concomitant use with dofetilide
- Moderate or severe hepatic impairment
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, rash, dizziness, nausea, abdominal pain, vomiting, fatigue
Serious Skin and hypersensitivity reactions including DRESS, hepatotoxicity, depressive disorders
Postmarketing Nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Most common (>=2%) Insomnia, headache, fatigue, nausea, diarrhea
Serious Serious and sometimes fatal hypersensitivity reaction with abacavir, exacerbations of hepatitis B, hepatotoxicity, lactic acidosis and severe hepatomegaly with steatosis, immune reconstitution syndrome, myocardial infarction
Postmarketing Aplastic anemia, anemia, lymphadenopathy, splenomegaly, stomatitis, pancreatitis, acute liver failure, sensitization reactions including anaphylaxis and urticaria, weight increase, hyperlactemia, CPK elevation, muscle weakness, myalgia, rhabdomyolysis, peripheral neuropathy, seizures, anxiety, alopecia, erythema multiforme, suspected Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
TRIUMEQ and TRIUMEQ PD are fixed-dose combinations of three HIV-1 antiretroviral agents: dolutegravir (an integrase strand transfer inhibitor that blocks HIV replication by binding to the integrase active site and inhibiting the strand transfer step), abacavir (a nucleoside analogue that is converted to carbovir triphosphate which inhibits HIV-1 reverse transcriptase by competing with dGTP and incorporating into viral DNA), and lamivudine (a nucleoside analogue phosphorylated to lamivudine triphosphate which inhibits reverse transcriptase via DNA chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edurant
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (11/12)
Triumeq
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Edurant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Triumeq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Edurant
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Triumeq
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EdurantView full Edurant profile
TriumeqView full Triumeq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.